Vertex Pharmaceuticals announced a reimbursement agreement with NHS England for individuals 12 years or older with transfusion-dependent...

Last week, Adam Coughlin and Luca Cericola from Bristows’ Commercial IP team attended ON Helix 2024, an annual conference hosted by One...

It's hard to believe that six months have passed since we released the 11th edition of our Biotech Review of the Year publication. Our...

This article was first published in The Licensing Journal (Volume 44, Number 4). You can read and/or download it, in full, below: Cell...

Bristows was delighted to sponsor and attend this year’s EU Pharmaceutical Law Forum, which was held in Brussels at the Steigenberger...

Cell and gene therapies (CGTs) continue to hold considerable promise for the future of medicine, providing unprecedented therapeutic...

This article is part of our Biotech Review of the Year - Issue 11 publication The biopharmaceutical landscape is undergoing a steady but...

This article is part of our Biotech Review of the Year - Issue 11 publication CRISPR technology has come on leaps and bounds in the last...

2023 is likely to be remembered as a year in which a number of highly anticipated developments in the biotech industry finally came to...

This article discusses the first CRISPR therapy seeks regulatory approval, raising the question but will it be able to avoid the pitfalls...

European Commission proposes to ease the regulatory burden for gene-edited plants. But when will it become law, and in what form? The...

Last month Adam Coughlin and Erik Müürsepp from Bristows’ Commercial IP team had the opportunity to attend the annual conference of...